Astellas Has a $6 Billion Hole in Its Revenue. Here's How It Plans to Fill It.
Astellas Pharma's biggest drug generates over 40% of its revenue and loses U.S. patent protection in 2027. The company just laid out an aggressive plan to buy, partner, and cut its way through the storm, and it's adding serious heat to an already competitive biotech M&A market.
Imagine a massive chunk of your paycheck vanishing in 18 months. That's basically where Astellas Pharma finds itself right now.
The Japanese drugmaker just unveiled a new five-year corporate strategic plan on May 26, and the subtext was impossible to miss: Astellas is going shopping. The company is positioning itself as an active acquirer and dealmaker, armed with a cost-cutting war chest and a growing roster of newer drugs. The reason? Its biggest moneymaker is about to lose patent protection, and the clock is ticking loud.
The Xtandi Problem
Xtandi, a blockbuster prostate cancer drug, accounts for roughly 25-30% of Astellas' total revenue. That's not diversification; that's dependence. And the substance patent on Xtandi expires in the U.S. in August 2027, with generic competition expected to follow in other major markets.
When a small-molecule drug like Xtandi loses patent protection, generics flood in fast. We're talking 60-80% of prescription volume potentially shifting to cheaper copies within a year or two. For a company that built its house on one drug, that's not a crack in the foundation; it's a sinkhole.
To make matters worse, Astellas' overactive bladder drug mirabegron (Myrbetriq) also faces competitive pressures as its patent lifecycle matures. So the pressure isn't coming from one direction. It's a pincer move.
The Battle Plan: Spend Smart, Cut Deep
Astellas isn't panicking, but it's definitely moving with urgency. The new strategic plan lays out a two-pronged approach: aggressively pursue deals while simultaneously slashing costs.
On the cost side, Astellas launched what it calls a "sustainable margin transformation" program back in 2024. It already squeezed out about 11 billion yen in SG&A savings in fiscal 2025. For fiscal 2026, SG&A is expected to drop another 7%, landing around 800 billion yen. The bigger target: 200 billion yen in cumulative cost savings by 2030. That's roughly $1.3 billion, freed up through organizational restructuring, infrastructure streamlining, and reduced spending on mature products.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The company is also consolidating research sites. It's closing its Universal Cells office in Seattle (about 50 jobs affected), relocating some positions to South San Francisco and Westborough, Massachusetts. The layoffs will roll out in waves between July 2026 and April 2028.
All of this margin discipline serves a specific purpose: keeping the balance sheet flexible enough to do deals while absorbing the revenue hit from Xtandi's patent cliff.
The Shopping List
So what's Astellas looking to buy? Think of it like a restaurant owner who built a wildly popular steakhouse but now needs to add seafood, pasta, and a cocktail program before the beef supply gets cut.
Astellas has organized its deal-hunting around four R&D "primary focuses": immuno-oncology, genetic regulation, blindness and regeneration (ophthalmology), and targeted protein degradation. Within those buckets, the company is chasing clinical-stage assets in bladder cancer, prostate cancer, gastric and pancreatic cancers, lung cancer, and blood cancers.
The modalities they care about are equally specific: antibody-drug conjugates (ADCs), T-cell engagers, protein degraders, and gene and cell therapies. If you're a biotech with a Phase 2 degrader in prostate cancer or an ADC targeting Claudin 18.2 in gastric tumors, Astellas probably already has your number.
The proof that this isn't just talk? Look at the track record. In 2023, Astellas bought Iveric Bio for roughly $5.9 billion, a deal that gave it IZERVAY, an ophthalmology drug that represents a key long-term growth driver. That acquisition was explicitly designed to counter the oncology patent cliff. Earlier, Astellas acquired Audentes to build a gene therapy platform. More recently, it took a $50 million strategic stake in Taysha Gene Therapies (15% equity, plus exclusive licensing options), a classic "buy the option, not the whole house" move.
The Replacement Lineup
Astellas isn't betting everything on deals, though. It's already growing a bench of newer drugs meant to collectively replace Xtandi's revenue. The headliners include PADCEV (bladder cancer), IZERVAY (geographic atrophy, a serious eye condition), VYLOY (gastric cancer), and VEOZAH (menopause symptoms). Management expects these strategic brands to deliver double-digit growth and collectively drive the company forward.
For fiscal 2026, Astellas is guiding to revenue above 2.2 trillion yen and core operating profit above 600 billion yen, both above record levels. The company claims it is now "fully prepared to overcome Xtandi's loss of exclusivity and to continue to grow." Bold words. The market will be watching to see if the numbers back them up.
The strategic plan also calls for 10 or more Phase 3 studies to begin between fiscal 2026 and 2030, with at least five starting by fiscal 2027. That cadence suggests a company trying to create a conveyor belt of new drugs rather than scrambling for a single replacement.
Why the Broader Market Should Care
Astellas isn't the only pharma company staring down a patent cliff. Across the industry, somewhere between $200 and $350 billion in annual drug sales are exposed to loss of exclusivity by the early 2030s. Keytruda, Opdivo, Imbruvica, Trulicity: the list of blockbusters approaching their expiration dates reads like a pharma hall of fame.
This collective pressure has turned the biotech M&A market into something resembling a crowded auction house. Biopharma M&A activity surged dramatically in 2025. Pfizer, Merck, J&J, Novartis, and Sanofi have all made multi-billion-dollar acquisitions in the past year. Pfizer even won a bidding war against Novo Nordisk for Metsera, an obesity-focused biotech, in a deal worth up to $10 billion.
Adding Astellas to the active-buyer pool raises the stakes for everyone. More buyers chasing a finite number of quality clinical-stage assets means higher valuations for the best programs and more competitive auction processes. If you're a biotech with a de-risked, Phase 2 oncology program in a hot modality like ADCs or protein degraders, congratulations: you're the house in a seller's market.
But the dynamics are a barbell. Top-tier assets with strong clinical data attract multiple bidders and premium prices. Everything else? Crickets. Analysts describe a market that's "very selective" at the individual asset level, even as macro urgency is sky-high.
The Bottom Line
Astellas is playing a game that every mid-size pharma company fears: replacing a franchise that made the company what it is today. The plan is disciplined (targeted bolt-ons, not a reckless megamerger), the financial cushion is being built (200 billion yen in savings), and the replacement drugs are growing. Whether it's enough to smoothly bridge a major revenue gap, nobody knows for sure. But one thing is clear: Astellas has its wallet out, and the biotech M&A market just got a little more crowded.
4 min read
The FDA Just Asked the Internet How to Use AI in Drug Trials
The FDA just asked the public to help design an AI clinical trial pilot program, with selections planned for August 2026. This isn't a vague exploration; it's a live procurement process that could set the rules for AI in drug development for years to come.
